- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Illumina Inc (ILMN)
Illumina Inc stock price live, this page displays NASDAQ ILMN stock exchange data. View the ILMN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Illumina Inc real time stock price chart below.
What Is the Illumina Inc Stock Price Today?
The Illumina Inc stock price today is 100.80.
What Is the Stock Symbol for Illumina Inc?
The stock symbol for Illumina Inc is ""ILMN.""
What Stock Exchange Does Illumina Inc Trade On?
Illumina Inc is listed and trades on the NASDAQ stock exchange.
Is Illumina Inc a Good Stock to Buy?
Determining whether Illumina Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ILMN quote. (ISIN: US4523271090)
What Is the Illumina Inc Stock Price Today?
The Illumina Inc stock price today is 100.80.
What Is the Stock Symbol for Illumina Inc?
The stock symbol for Illumina Inc is ""ILMN.""
What Stock Exchange Does Illumina Inc Trade On?
Illumina Inc is listed and trades on the NASDAQ stock exchange.
Is Illumina Inc a Good Stock to Buy?
Determining whether Illumina Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ILMN quote. (ISIN: US4523271090)
Fair Value
An estimate of a Illumina's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
99.25
101.19
52 wk Range
68.70
156.66
ILMN Scorecard
Full Analysis
Management has been aggressively buying back shares
ILMN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Illumina's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
99.25101.19
52 wk Range
68.70156.66
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ILMN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Illumina's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
112.05
Upside
+11.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
16 analysts have revised their earnings upwards for the upcoming period
- Illumina, inc. receives Investment Bank Analyst Rating Update
- Investing.com
Pro - BioStem Technologies names Brandon Poe as new CFO
- Investing.com
- Illumina, inc. receives Investment Bank Analyst Rating Update
- Investing.com
Pro - BioStem Technologies appoints Brandon Poe as new CFO
- Investing.com
- BioStem Technologies names Brandon Poe as new CFO
- Investing.com
- BioStem Technologies appoints Brandon Poe as new CFO
- Investing.com
- Illumina, inc. receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Illumina, inc. receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Illumina Inc Company Profile
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Illumina Inc SWOT Analysis
Genetic Giant's Dilemma | Illumina, a leader in DNA sequencing, faces critical challenges as it navigates technological innovation, market competition, and geopolitical tensions, particularly with China. |
NovaSeq X Revolution | Explore how Illumina's NovaSeq X platform could transform the genetic analysis market by reducing sequencing costs threefold and potentially driving significant demand elasticity. |
China Conundrum | Delve into the implications of Illumina's addition to China's "unreliable entity list," which could erase $300 million in sales and significantly impact the company's growth prospects. |
Analyst Perspectives | Analysts project a 7% revenue CAGR through 2027, with price targets ranging from $90 to $254, reflecting diverse views on Illumina's ability to overcome current challenges. |
Illumina Inc Earnings Call Summary for Q2/2025
- Illumina beats Q2 2025 EPS forecast by 17.8%, reporting $1.19 vs $1.01 expected; revenue slightly above at $1.06B
- Despite earnings beat, stock fell 3.57% after-hours; company remains unprofitable over last 12 months
- Non-GAAP operating margin improved to 23.8%, up 160 basis points; revenue down 3% YoY due to research market constraints
- FY2025 guidance: revenue $4.23B-$4.31B, operating margin 22-22.5%, EPS $4.45-$4.55; expects improved growth in 2026 and 2027
- CEO highlights potential in genomic sequencing market; clinical space seen as key growth driver amid ongoing research challenges
Last Updated: 31/07/2025, 23:50
Read Full TranscriptCompare ILMN to Peers and Sector
Metrics to compare | ILMN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipILMNPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.7x | −0.6x | |
PEG Ratio | −0.69 | 0.01 | 0.00 | |
Price/Book | 0.0x | 1.0x | 2.6x | |
Price / LTM Sales | 0.0x | 3.6x | 3.3x | |
Upside (Analyst Target) | −1.1% | 22.2% | 39.5% | |
Fair Value Upside | Unlock | −8.1% | 4.9% | Unlock |
Analyst Ratings
9 Buy
10 Hold
3 Sell
Ratings:
22 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 112.05
(+11.16% Upside)
Earnings
Latest Release
Jul 31, 2025
EPS / Forecast
1.19 / 1.01
Revenue / Forecast
1.06B / 1.05B
People Also Watch
FAQ
What Stock Exchange Does Illumina Trade On?
Illumina is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Illumina?
The stock symbol for Illumina is "ILMN."
What Is the Illumina Market Cap?
As of today, Illumina market cap is 16.07B.
What Is Illumina's Earnings Per Share (TTM)?
The Illumina EPS (TTM) is 7.93.
When Is the Next Illumina Earnings Date?
Illumina will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is ILMN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Illumina Stock Split?
Illumina has split 1 times.
How Many Employees Does Illumina Have?
Illumina has 9000 employees.
What is the current trading status of Illumina (ILMN)?
As of 21 Aug 2025, Illumina (ILMN) is trading at a price of 100.80, with a previous close of 101.60. The stock has fluctuated within a day range of 99.25 to 101.19, while its 52-week range spans from 68.70 to 156.66.
What Is Illumina (ILMN) Price Target According to Analysts?
The average 12-month price target for Illumina is USD112.04762, with a high estimate of USD185 and a low estimate of USD75. 9 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an +11.16% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.